Prime Medicine, Inc.
PRME
$4.04
$0.308.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.85M | 2.98M | 800.00K | 591.00K | 591.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.85M | 2.98M | 800.00K | 591.00K | 591.00K |
| Cost of Revenue | 120.37M | 120.24M | 127.60M | 128.22M | 119.75M |
| Gross Profit | -116.53M | -117.26M | -126.80M | -127.63M | -119.16M |
| SG&A Expenses | 52.29M | 50.16M | 50.94M | 47.34M | 45.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 210.36M | 205.45M | 213.59M | 210.61M | 200.19M |
| Operating Income | -206.52M | -202.47M | -212.79M | -210.02M | -199.60M |
| Income Before Tax | -202.15M | -195.88M | -219.25M | -217.55M | -204.44M |
| Income Tax Expenses | -134.00K | 0.00 | 0.00 | -108.00K | 57.00K |
| Earnings from Continuing Operations | -202.01 | -195.88 | -219.25 | -217.44 | -204.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -202.01M | -195.88M | -219.25M | -217.44M | -204.50M |
| EBIT | -206.52M | -202.47M | -212.79M | -210.02M | -199.60M |
| EBITDA | -200.01M | -196.34M | -207.13M | -204.68M | -194.68M |
| EPS Basic | -1.62 | -1.66 | -2.05 | -2.16 | -2.17 |
| Normalized Basic EPS | -1.02 | -1.06 | -1.22 | -1.28 | -1.30 |
| EPS Diluted | -1.62 | -1.66 | -2.05 | -2.16 | -2.17 |
| Normalized Diluted EPS | -1.02 | -1.06 | -1.22 | -1.28 | -1.30 |
| Average Basic Shares Outstanding | 500.76M | 474.34M | 435.89M | 407.97M | 379.25M |
| Average Diluted Shares Outstanding | 500.76M | 474.34M | 435.89M | 407.97M | 379.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |